Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance (palbociclib) Read more
eFFECTOR Enters Into Agreement with Pfizer to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types Read more
Iovance and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement Read more